prucalopride / Generic mfg. - LARVOL DELTA

Anti-inflammatory Effect of Pre-operative Stimulation of the Cholinergic Anti-Inflammatory Pathway (clinicaltrials.gov) - P4 | N=31 | Completed | Sponsor: KU Leuven | Recruiting ➔ Completed

Trial completion

Continuous Coagulation Monitoring in Human Blood Samples via Magnetic Particle Spectroscopy. (PubMed, Int J Nanomedicine) - "With the clinical approval of Resotran as an MPI-suitable tracer and the development of first human-scale scanners, clinical applications are within reach...The signal amplitude of the fifth harmonic of the MPS was analyzed...Additionally, mechanical stress induced a signal decay in all samples, further indicating the link between the observed MPS signal decay and blood coagulation. This study shows that continuous monitoring of human blood coagulation via MPS is feasible, making bedside coagulation monitoring in clinical settings a concrete perspective."

Journal

Central and Peripheral Neuromodulators in Functional Dyspepsia and Gastroparesis: A Symptom-Based Clinical Review. (PubMed, Neurogastroenterol Motil) - "Neuromodulators provide a rational, mechanism-based treatment option for FD and GP, and a symptom-oriented approach may optimize patient outcomes; although high-quality, subtype-specific trials are needed to strengthen the evidence base."

Journal • Review • Cardiovascular • CNS Disorders • Dyspepsia • Gastrointestinal Disorder • Immunology • Infectious Disease • Musculoskeletal Pain • Pain • Psychiatry

38RC24.0407: Etude de phase II valuant la capacit d'un agoniste des rcepteurs 5-HT4, le prucalopride (Resolor), acclrer l'efficacit thrapeutique d'un antidpresseur de type ISRS: preuve de concept clinique. (clinicaltrialsregister.eu) - P1/2 | N=70 | Not yet recruiting | Sponsor: Centre Hospitalier Universitaire Grenoble Alpes

New P1/2 trial

Prucalopride Treatment for Refractory Gastro-esophageal Reflux Disease (clinicaltrials.gov) - P4 | N=60 | Recruiting | Sponsor: Universitaire Ziekenhuizen Leuven

New P4 trial • Gastroenterology • Gastroesophageal Reflux Disease

IMPACT OF PRUCALOPRIDE ON GASTRIC MYOELECTRICAL ACTIVITY AND ANTRODUODENAL MANOMETRY (DDW 2026) - No abstract available

Pediatrics

Slow Transit Constipation: Pathophysiological Perspectives and Management Updates. (PubMed, J Dig Dis) - "The treatment of STC should follow a stepwise approach, beginning with dietary and lifestyle modification, osmotic and stimulant laxatives, and prokinetics such as prucalopride...Although advances in understanding STC pathophysiology are guiding novel therapeutic development, robust randomized controlled trials remain scarce. Optimal care requires multidisciplinary collaboration between gastroenterologists, colorectal surgeons, and pelvic floor specialists to ensure accurate diagnosis, tailored treatment, and improved long-term outcomes."

Journal • Review • Constipation • Gastroenterology • Gastrointestinal Disorder • Transplantation

Prucalopride, a serotonin type 4 receptor agonist, induces fast anxiolytic/antidepressant effects and concomitant changes in the gut microbiota. (PubMed, NPJ Biofilms Microbiomes) - "Behavioral effects of prucalopride (0.5 and 1.5 mg/kg/day) were compared to fluoxetine, a common SSRI, over 7 (subchronic) and 28 (chronic) days. Notably, prucalopride restored levels of the genus Ruminococcus, which were depleted by CORT. Our findings highlight prucalopride's rapid anxiolytic and antidepressant-like effects and its impact on gut microbiota, supporting the potential of 5-HT4R-targeting molecules as therapeutic options for psychiatric disorders."

Journal • CNS Disorders • Constipation • Depression • Gastroenterology • Gastrointestinal Disorder • Major Depressive Disorder • Mental Retardation • Mood Disorders • Psychiatry

Gastrointestinal Dysmotility on Aspiration Risk (clinicaltrials.gov) - P4 | N=120 | Recruiting | Sponsor: Boston Children's Hospital | Not yet recruiting ➔ Recruiting

Enrollment open • Gastroenterology • Gastroesophageal Reflux Disease • Gastrointestinal Disorder • Infectious Disease • Pneumonia • Respiratory Diseases

Effect of Linaclotide on Colonic Motility Assessed With Intraluminal Colonic High-Resolution Manometry in Healthy Subjects. An Acute, Open Label, Randomized, Crossover, Reader-Blinded Study. (PubMed, Neurogastroenterol Motil) - "In healthy controls, acute administration of linaclotide increases the total number of long-distance propagating sequences and the pre-prandial pancolonic pressurizations."

Journal • Colorectal Cancer • Constipation • Gastroenterology • Gastrointestinal Disorder

Prucalopride for Cognitive Functioning in Schizophrenia (clinicaltrials.gov) - P=N/A | N=34 | Not yet recruiting | Sponsor: University of Pittsburgh | Trial primary completion date: Aug 2026 ➔ Dec 2026

Trial primary completion date • CNS Disorders • Psychiatry • Schizophrenia

A Study to Assess Maternal and Fetal Outcomes After Taking Prucalopride During Pregnancy (clinicaltrials.gov) - P=N/A | N=100 | Active, not recruiting | Sponsor: Takeda | Trial completion date: Dec 2025 ➔ Dec 2026 | Trial primary completion date: Dec 2025 ➔ Dec 2026

Trial completion date • Trial primary completion date • Constipation • Gastroenterology • Gastrointestinal Disorder

Bali Chronic Constipation Roundtable Report: Chronic Constipation Management in Asia. (PubMed, J Neurogastroenterol Motil) - "First line therapies such as dietary-fiber optimization and osmotic laxatives are widely available, but newer pharmacotherapies (prucalopride, linaclotide, lubiprostone, and elobixibat) remain costly and unevenly accessible. The Bali Chronic Constipation Roundtable highlighted Asia's need for region specific diagnostics and management. Addressing diagnostic and treatment gaps will improve outcomes, while ongoing researcher clinician policy collaboration must standardize guidelines, advance research, and ensure equitable care across Asia."

Journal • Constipation • Gastroenterology • Gastrointestinal Disorder

Pathophysiological mechanisms, diagnostic innovations, and multimodal therapeutic strategies for slow transit constipation. (PubMed, BMC Gastroenterol) - No abstract available

Journal • Constipation • Gastroenterology • Gastrointestinal Disorder

New Delhi: In a significant regulatory development, Torrent Pharmaceuticals has got the go-ahead from the Subject Expert Committee (SEC) under the Central Drugs Standard Control Organisation (CDSCO) to manufacture and market Prucalopride Oral Solution 0.2 mg/mL. (Medical Dialogues)

Approval • Constipation

An Intriguing Case of Hypermobile Ehlers-Danlos Syndrome Presenting With Severe Gut Dysmotility and Refractory Gastroparesis (ACG 2025) - "Full-thickness biopsy via laparoscopic gastric pacemaker placement revealed fibrosis of the myenteric plexus with sparse ganglion cells. Despite trials of metoclopramide, erythromycin, domperidone, and prucalopride, the patient exhibited minimal clinical improvement. Early recognition, combined with integrative care, is critical. As awareness of hEDS-related GI dysfunction grows, more systematic investigation is needed to inform targeted therapies and long-term outcomes."

Clinical • Fibrosis • Gastrointestinal Disorder • Genetic Disorders • Immunology • Rheumatology

Fast and Frequent: How Effective Is Prucalopride in Chronic Constipation? A Systematic Review and Meta-Analysis of Randomized Controlled Trial (ACG 2025) - "We included seven RCTs comprising 3,389 patients, of whom 2,020 were randomized to receive prucalopride. The mean age was 48.1 years, 76.1% were women, and the average duration of constipation was 16.1 years. Approximately 80% had an inadequate response to prior treatments, and 66% reported fewer than one bowel movement per week at baseline."

Retrospective data • Review • Constipation • Gastroenterology • Gastrointestinal Disorder

ALS Complicated with Ogilvie's Syndrome (ACG 2025) - "Riluzole 50 mg BID was started...He was managed with nasogastric suction, pyridostigmine 60 mg BID, and prucalopride, but symptoms persisted...Pyridostigmine was tried but showed limited effectiveness. Constipation in patients with ALS should be approached with caution, as it may indicate the development of Ogilvie syndrome."

Amyotrophic Lateral Sclerosis • CNS Disorders • Constipation • Gastroenterology • Gastrointestinal Disorder • Inflammation • Movement Disorders • Muscle Spasticity

Comparative Efficacy of Pharmacologic Therapies for Gastroparesis: A Systematic Review and Network Meta-Analysis (ACG 2025) - "Interventions included prucalopride, cisapride, revexepride, metoclopramide, relamorelin, TZP-102, aprepitant, tradipitant, cannabidiol (CBD), and domperidone. A total of 21 trials comprising 2,452 patients were included in the study. For symptom improvement, 19 studies that compared 10 treatments contributed to the network. Cisapride (SMD, 1.88; 95% CI –2.71 to –1.06; SUCRA=0.98), relamorelin (SMD, 1.15; 95% CI –2.15 to –0.16; SUCRA=0.86), and aprepitant (SMD: 0.60; 95% CI –0.88 –0.32; SUCRA=0.76) significantly outperformed the placebo."

Retrospective data • Review • Gastrointestinal Disorder

The Last Stand: Intravenous Immunoglobulin Treatment for Recurrent Pseudo-Obstruction Secondary to Scleroderma (ACG 2025) - "In the previous 6 months, he had 5 admissions for management of his PO despite trials of prucalopride and erythromycin. The use of IVIG in a few case reports has shown to assist with symptom improvement and weight gain, however, no formal study on its efficacy and impact on readmission exists. Our patient demonstrated a positive response to IVIG treatment and a reduction in readmission supporting its use for recurrent SSc PO.Figure: Figure 1: CT abdomen and pelvis with oral contrast demonstrating small bowel dilation with a focal narrowing in the distal ileum.Figure: Figure 2: X-ray of the abdomen demonstrating small bowel dilation with minimal passage of oral contrast into the colon prior to initiation of IVIG treatment (a) and with improved and stable PO post-IVIG treatment (b)."

Immunology • Inflammation • Rheumatology • Scleroderma • Systemic Sclerosis

Uncharted Territory: The Secretory Diarrhea Variant of Ogilvie's Syndrome (ACG 2025) - "Promotility agents like prucalopride and erythromycin have been successful in isolated case reports but were declined by him due to their adverse effects...He was discharged with a follow-up after hypokalemia resolved with spironolactone, octreotide, and daily potassium repletion. The secretory diarrhea variant of Ogilvie's syndrome is a rare disease...There are only a few case reports on this disease but no standard guidelines. This case seeks to help in the management of this disease through the use of aldosterone antagonists and somatostatin analogs.Figure: Computed tomography (CT) scan of the abdomen showing colonic dilatation without a transition point.Figure: Computed tomography (CT) scan of the abdomen showing colonic dilatation without a transition point."

Asthma • Cardiovascular • Chronic Kidney Disease • Constipation • Gastroenterology • Gastrointestinal Disorder • Immunology • Infectious Disease • Metabolic Disorders • Nephrology • Rare Diseases • Renal Disease • Respiratory Diseases

Uncommon Culprit: Sarcina Ventriculi Causing Gastric Ulceration in a Gastroparetic Patient (ACG 2025) - "She was given metoclopramide, rifaximin, and prucalopride with no relief...She was treated with nasogastric decompression which provided improvement and discharged on intranasal metoclopramide...Ultimately, while S.ventriculi may not be pathogenic in all cases, its detection, particularly in patients with gastroparesis should prompt physicians to consider antibiotic therapy and repeat biopsies. Growing recognition of this organism and its potential pathogenicity may hopefully lead to formalized treatment guidelines."

Clinical • Gastroenterology • Gastrointestinal Disorder • Infectious Disease • Peptic Ulcer • Respiratory Diseases

In Hot Water: Neurogastroenterology and Motility Sequelae of Cytoreductive Surgery (CRS) Plus Hyperthermic Intraperitoneal Chemotherapy (HIPEC) (ACG 2025) - "We present a case series of neurogastroenterology and motility sequelae in 3 patients with abdominal cancers and peritoneal metastasis who were treated with cytoreductive surgery (CRS) + hyperthermic intraperitoneal chemotherapy (HIPEC).Case Description/ 58-year-old female with high grade appendiceal cancer underwent right hemicolectomy, peritonectomy, omentectomy + HIPEC (Mitomycin-C)...A diagnosis of chronic intestinal pseudo-obstruction (CIPO) was made and she was successfully treated with prucalopride and pyridostigmine.47-year-old female with stage IVB serous ovarian cancer underwent hysterectomy, bilateral salpingo-oophorectomy, peritonectomy, omentectomy and right hemicolectomy followed by adjuvant chemotherapy. PET/CT scan showed recurrent peritoneal metastases requiring secondary cytoreduction + HIPEC (cisplatin/paclitaxel)...Symptoms improved remarkably on pancreatic enzyme replacement therapy.76-year-old male with stage IV sigmoid colon cancer underwent..."

Surgery • Alopecia • Appendix Cancer • Colon Cancer • Colorectal Cancer • Gastric Cancer • Gastrointestinal Disorder • Gynecology • Immunology • Ovarian Cancer • Ovarian Serous Adenocarcinoma • Peritoneal Cancer • Solid Tumor

New Kid on the Block: Could Suzetrigine's Promise of Pain Relief Improve Outcomes in Management of DGBI? (ACG 2025) - "He tried linaclotide, plecanatide, lubiprostone, prucalopride, and tenapanor...Adjunct pharmacological neuromodulators like nortriptyline, duloxetine and gabapentin were not helpful...She responded partially to duloxetine, buspirone, mirtazapine, and cognitive behavioral therapy...Studies have directly and indirectly established the importance of NaV1.8 to visceral pain perception (Table 1). Additional trials are needed to evaluate the impact of this medicine on visceral pain perception especially in conditions associated with acute and/or chronic abdominal pain, including DGBIs.Figure: Summary of Studies Supporting the Role of Nav1.8 in Visceral Pain Perception"

Cardiovascular • CNS Disorders • Constipation • Gastroenterology • Gastrointestinal Disorder • Infectious Disease • Mood Disorders • Novel Coronavirus Disease • Pain • Psychiatry • NAV1

Bowel Preparation Quality in Elderly vs Younger Adults: Implications for Colorectal Cancer Screening (ACG 2025) - "Adjunctive agents like simethicone and prucalopride also enhanced mucosal visibility. Physiological and logistical limitations restrict many elderly adults from achieving the necessary bowel preparation for colonoscopy. Among 3,436 elderly patients, bowel prep adequacy ranged from 65.4% to 81.1% and was significantly lower than younger cohorts (77.3%-94.4%). Common risk factors for poor prep included: male sex, type 2 diabetes, constipation, impaired mobility and lack of support. Mean BBPS scores were lower in the elderly patients: 6.3 vs 6.6."

Clinical • Alzheimer's Disease • Cognitive Disorders • Colorectal Cancer • Constipation • Diabetes • Gastroenterology • Gastrointestinal Disorder • Metabolic Disorders • Oncology • Solid Tumor • Type 2 Diabetes Mellitus